Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 4 complete abstracts (658 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
Progressive deterioration of T-cell function due to chronic antigen stimulation and inflammatory signals, e.g., chronic infection and cancer. T-cell exhaustion is characterized by weakened immune system, e.g., dysfunctional memory T cells differentiation and epigenetic repression of immunologic memory effector functions.
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: Exhaustion, T-Cell; T Cell Exhaustion; T-Lymphocyte Exhaustion; Exhaustions, T-Lymphocyte; Exhaustion, T-Lymphocyte; T Lymphocyte Exhaustion; T-Lymphocyte Exhaustions.
Where it fits in the MeSH classification
- Broader topics
- Immune System Exhaustion
- See also
- Lymphocyte Depletion; T-Cell Senescence
Related concepts
- Chronic Infection
- Neoplasms
- Memory
- Cells
- Epigenetic Repression
- Immunologic Memory
Research landscape
PubMed indexes 999 records tagged with the MeSH heading “T-Cell Exhaustion” (counts retrieved 2026-10-29). 998 of them (99.9%) were published from 2020 onward, and the busiest period so far is 2020 onward with 998 records.
Reviews account for 242 records (24.2%) and meta-analyses for 0. Randomized controlled trials number 1 (0.1%) as a share of all records on the topic. Randomized trials make up only a small share of this literature, so much of what is known comes from laboratory, observational or descriptive work.
Show the data
| Period | Records |
|---|---|
| through 1999 | 1 |
| 2000-2009 | 0 |
| 2010-2019 | 0 |
| 2020 onward | 998 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 242 | 24.2% |
| Meta-analyses | 0 | 0.0% |
| Randomized controlled trials | 1 | 0.1% |
Method: PubMed query "T-Cell Exhaustion"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-29.
Reading the evidence in immunology
Immune responses are studied in model organisms, in cells from donors and in patients, and the same pathway can behave differently across these settings. Mouse immune systems differ from human ones in important ways, and blood measurements may not reflect what happens in tissues. Clinical conclusions about immune-mediated disease or immunotherapy come mainly from controlled trials and long-term cohorts. Check the species and tissue studied, whether markers were linked to outcomes patients notice, and the follow-up time.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
| Study / authors | Year | Source label / design | Europe PMC citations | Licence / source |
|---|---|---|---|---|
| Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy | 2023 | Research article Design not recorded in structured metadata | 94 | cc by PMID 36732507 · DOI · PMC9895440 |
| Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML | 2023 | Research article Design not recorded in structured metadata | 59 | cc by PMID 37106163 · DOI · PMC10244166 |
| T-cell exhaustion and stemness in antitumor immunity: Characteristics, mechanisms, and implications | 2023 | Review article Design not recorded in structured metadata | 57 | cc by PMID 36891319 · DOI · PMC9986432 |
| T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities | 2026 | Review article Design not recorded in structured metadata | 20 | cc by PMID 41527444 · DOI · PMC13292197 |
Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy [1]
Abstract reading summary — source excerpts
- Opening excerpt
- Tumor-specific T cells are frequently exhausted by chronic antigenic stimulation.
- Closing excerpt
- Our findings highlight that targeting SNX9 is a strategy to prevent T cell exhaustion and enhance anti-tumor immunity.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (141 words)
Tumor-specific T cells are frequently exhausted by chronic antigenic stimulation. We here report on a human antigen-specific ex vivo model to explore new therapeutic options for T cell immunotherapies. T cells generated with this model resemble tumor-infiltrating exhausted T cells on a phenotypic and transcriptional level. Using a targeted pooled CRISPR-Cas9 screen and individual gene knockout validation experiments, we uncover sorting nexin-9 (SNX9) as a mediator of T cell exhaustion. Upon TCR/CD28 stimulation, deletion of SNX9 in CD8 T cells decreases PLCγ1, Ca2+, and NFATc2-mediated T cell signaling and reduces expression of NR4A1/3 and TOX. SNX9 knockout enhances memory differentiation and IFNγ secretion of adoptively transferred T cells and results in improved anti-tumor efficacy of human chimeric antigen receptor T cells in vivo. Our findings highlight that targeting SNX9 is a strategy to prevent T cell exhaustion and enhance anti-tumor immunity.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 36732507 · DOI · PMC9895440
Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML [2]
Abstract reading summary — source excerpts
- Opening excerpt
- Although the landscape for treating acute myeloid leukemia (AML) patients has changed substantially in recent years, the majority of patients will eventually relapse and succumb to their disease.
- Closing excerpt
- As T-cell exhaustion and target antigen heterogeneity are well-known causes of resistance, the AdCAR platform might offer effective strategies to ameliorate these limitations.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (191 words)
Although the landscape for treating acute myeloid leukemia (AML) patients has changed substantially in recent years, the majority of patients will eventually relapse and succumb to their disease. Allogeneic stem cell transplantation provides the best anti-AML treatment strategy, but is only suitable in a minority of patients. In contrast to B-cell neoplasias, chimeric antigen receptor (CAR) T-cell therapy in AML has encountered challenges in target antigen heterogeneity, safety, and T-cell dysfunction. We established a Fab-based adapter CAR (AdCAR) T-cell platform with flexibility of targeting and control of AdCAR T-cell activation. Utilizing AML cell lines and a long-term culture assay for primary AML cells, we were able to demonstrate AML-specific cytotoxicity using anti-CD33, anti-CD123, and anti-CLL1 adapter molecules in vitro and in vivo. Notably, we show for the first time the feasibility of sequential application of adapter molecules of different specificity in primary AML co-cultures. Importantly, using the AML platform, we were able to demonstrate that chronic T-cell stimulation and exhaustion can be counteracted through introduction of treatment-free intervals. As T-cell exhaustion and target antigen heterogeneity are well-known causes of resistance, the AdCAR platform might offer effective strategies to ameliorate these limitations.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 37106163 · DOI · PMC10244166
T-cell exhaustion and stemness in antitumor immunity: Characteristics, mechanisms, and implications [3]
Abstract reading summary — source excerpts
- Opening excerpt
- T cells play a crucial role in the regulation of immune response and are integral to the efficacy of cancer immunotherapy.
- Closing excerpt
- Moreover, we discuss therapeutic strategies to overcome T-cell immunodeficiency in the tumor microenvironment and promote continuous breakthroughs in the anticancer activity of T cells.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (114 words)
T cells play a crucial role in the regulation of immune response and are integral to the efficacy of cancer immunotherapy. Because immunotherapy has emerged as a promising treatment for cancer, increasing attention has been focused on the differentiation and function of T cells in immune response. In this review, we describe the research progress on T-cell exhaustion and stemness in the field of cancer immunotherapy and summarize advances in potential strategies to intervene and treat chronic infection and cancer by reversing T-cell exhaustion and maintaining and increasing T-cell stemness. Moreover, we discuss therapeutic strategies to overcome T-cell immunodeficiency in the tumor microenvironment and promote continuous breakthroughs in the anticancer activity of T cells.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 36891319 · DOI · PMC9986432
T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities [4]
Abstract reading summary — source excerpts
- Opening excerpt
- T cell exhaustion represents a pivotal mechanism of immune escape in cancer, with its inherent heterogeneity and dynamic plasticity being key determinants of the variable responses and resistance to immune checkpoint inhibitors (ICIs).
- Closing excerpt
- Finally, we discuss prevailing challenges and future directions, emphasizing that deciphering the heterogeneous landscape of TEX cells, identifying precise biomarkers, and developing temporally controlled combination regimens are imperative to effectively reverse T cell exhaustion and broaden the therapeutic efficacy of cancer immunotherapy.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (212 words)
T cell exhaustion represents a pivotal mechanism of immune escape in cancer, with its inherent heterogeneity and dynamic plasticity being key determinants of the variable responses and resistance to immune checkpoint inhibitors (ICIs). This review comprehensively delineates the multifaceted heterogeneity of exhausted T (TEX) cells, tracing their developmental trajectory from precursor exhausted T (TPEX) cells to terminally differentiated exhausted T (TEX -term) cells. We highlight both distinct and shared exhaustion features across diverse cancer types and spatial niches within the tumor microenvironment. Furthermore, we examine the multi-layer biomarkers that drive and define this state, including characteristic surface inhibitory receptors, core transcription factors, and metabolism-associated molecules. Grounded in this mechanistic understanding, we discuss emerging therapeutic strategies aimed at reversing T cell exhaustion. These range from the optimized application of ICIs and rational combination therapies involving epigenetic or metabolic interventions, to next-generation engineered cell therapies such as chimeric antigen receptor T cell (CAR-T), T cell receptor-engineered T cell (TCR-T), and tumor-infiltrating lymphocytes (TILs), alongside emerging modalities including oncolytic viruses and bispecific antibodies. Finally, we discuss prevailing challenges and future directions, emphasizing that deciphering the heterogeneous landscape of TEX cells, identifying precise biomarkers, and developing temporally controlled combination regimens are imperative to effectively reverse T cell exhaustion and broaden the therapeutic efficacy of cancer immunotherapy.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41527444 · DOI · PMC13292197
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article Cellular and molecular waypoints along the path of T cell exhaustion [5]
- Research article Terminally exhausted CD8+ T cells in solid tumors: biology, biomarker potential and translational tools for precision oncology [6]
- Research article Regulation of T cell exhaustion and stemness: molecular mechanisms and implications for cancer immunotherapy [7]
- Research article T-cell exhaustion from a multiomics perspective: Differentiation mechanisms and regulatory networks in the journey from progenitor-Exhausted T cells to terminally exhausted T cells [8]
- Research article Nutritional intervention alleviates T cell exhaustion and empowers anti-tumor immunity [9]
- Research article T Cell Exhaustion in Hepatocellular Carcinoma: A Substantial Barrier in Immunotherapy [10]
References
- Trefny MP, Kirchhammer N, Auf der Maur P, Natoli M, Schmid D, Germann M, et al.. Deletion of SNX9 alleviates CD8 T cell exhaustion for effective cellular cancer immunotherapy. . 2023. PMID 36732507 · DOI · PMC9895440
- Nixdorf D, Sponheimer M, Berghammer D, Engert F, Bader U, Philipp N, et al.. Adapter CAR T cells to counteract T-cell exhaustion and enable flexible targeting in AML. . 2023. PMID 37106163 · DOI · PMC10244166
- Chi X, Luo S, Ye P, Hwang WL, Cha JH, Yan X, et al.. T-cell exhaustion and stemness in antitumor immunity: Characteristics, mechanisms, and implications. . 2023. PMID 36891319 · DOI · PMC9986432
- Yu Y, Yao X, Wang Q, Yang M, Li R, Qin J, et al.. T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities. . 2026. PMID 41527444 · DOI · PMC13292197
- Lan X, Zebley CC, Youngblood B. Cellular and molecular waypoints along the path of T cell exhaustion. Sci Immunol. 2023. PMID 37656775 · DOI · PMC10618911
- Guo X, Ma S, Wang J, Fu Y, Ma W. Terminally exhausted CD8+ T cells in solid tumors: biology, biomarker potential and translational tools for precision oncology. Front Immunol. 2025. PMID 41601689 · DOI · PMC12833282
- Chen Z, Zhu Z, Hu T, Yao C, Wu T. Regulation of T cell exhaustion and stemness: molecular mechanisms and implications for cancer immunotherapy. Cell Mol Immunol. 2026. PMID 41413256 · DOI · PMC12753738
- Zhu T, Teng X, Jiao Q, Ren Y, Wang Y, Feng M. T-cell exhaustion from a multiomics perspective: Differentiation mechanisms and regulatory networks in the journey from progenitor-Exhausted T cells to terminally exhausted T cells. Clin Transl Med. 2026. PMID 41630529 · DOI · PMC12865229
- Xu Y, Yuan W, Li K, Li P. Nutritional intervention alleviates T cell exhaustion and empowers anti-tumor immunity. Front Immunol. 2025. PMID 41488640 · DOI · PMC12757304
- Nouri K, Asadollahei N, Haghir-Sharif-Zamini Y, Seydi H, Salehi M, Mesdaghi M, et al.. T Cell Exhaustion in Hepatocellular Carcinoma: A Substantial Barrier in Immunotherapy. J Cell Mol Med. 2026. PMID 41645702 · DOI · PMC12877428
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-10-29.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.